Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
VistaGen Therapeutics (VTGN)
NASDAQ:VTGN
VistaGen Therapeutics (VTGN) Stock Price & Analysis
714 Followers
VTGN Stock Chart & Stats
Day’s Range$4.66 - $4.75
52-Week Range― - ―
Previous Close$4.7
Volume35.27K
Average Volume (3M)N/A
Market Cap
$128.10M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
Jun 25, 2024EPS Estimate
-$0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$12.00Price Target Upside153.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
VistaGen Therapeutics News
PremiumPre-Earnings
Is VTGN a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentVTGN is advancing its clinical pipeline with two additional studies, PALISADE-3 and PALISADE-4, for social anxiety disorder, increasing the chances of successful NDA filing.
Market PotentialPH94B has the potential to become the first FDA-approved therapy for acute social anxiety disorder, addressing a significant market of over 25 million U.S. adults.
Regulatory MilestoneLead asset fasedienol (PH94B) is a fast-acting nasal spray with positive Phase III social anxiety data, boosting confidence in an upcoming FDA approval.
Bears Say
Clinical Study ChallengesSome KOLs believe that anxiety studies are even harder to execute than depression trials, as expectation bias and placebo effects can be very powerful.
Clinical Trial UncertaintyAlthough PH94B's first Phase III trial (PALISADE-1) missed the primary endpoint back in Q3:22, a subsequent (and identical) PALISADE-2 trial succeeded in Q3:23.
Uncertainty In Trial OutcomesThere's real risk that one of PALISADE-3 or -4 fails by simple chance; this is why it's important to have two shots-on-goal, but even for good anxiety drugs, there are no guarantees.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VTGN FAQ
What was VistaGen Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is VistaGen Therapeutics’s market cap?
Currently, no data Available
When is VistaGen Therapeutics’s upcoming earnings report date?
VistaGen Therapeutics’s upcoming earnings report date is Jun 25, 2024 which is in 66 days.
How were VistaGen Therapeutics’s earnings last quarter?
VistaGen Therapeutics released its earnings results on Feb 13, 2024. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.302 by $0.082.
Is VistaGen Therapeutics overvalued?
According to Wall Street analysts VistaGen Therapeutics’s price is currently Undervalued.
Does VistaGen Therapeutics pay dividends?
VistaGen Therapeutics does not currently pay dividends.
What is VistaGen Therapeutics’s EPS estimate?
VistaGen Therapeutics’s EPS estimate is -$0.36.
How many shares outstanding does VistaGen Therapeutics have?
Currently, no data Available
What happened to VistaGen Therapeutics’s price movement after its last earnings report?
VistaGen Therapeutics reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.302. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of VistaGen Therapeutics?
Currently, no hedge funds are holding shares in VTGN
---
VistaGen Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (153.16% Upside)
$12.00 (153.16% Upside)
Blogger Sentiment
Bullish
VTGN Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.69%
12-Months-Change
Fundamentals
Return on Equity
-44.55%
Trailing 12-Months
Asset Growth
341.18%
Trailing 12-Months
Company Description
VistaGen Therapeutics
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
---
VTGN Earnings Call
Q3 2024
0:00 / 0:00
---
VTGN Stock 12 Months Forecast
Average Price Target
$12.00
▲(153.16% Upside)
Technical Analysis
Citius Pharmaceuticals
―
Akari Therapeutics
―
Atea Pharmaceuticals
―
BioNano Genomics
―
Best Analysts Covering VTGN
1 Year
1 Year Success Rate
2/7 ratings generated profit
1 Year Average Return
-22.01%
reiterated a buy rating 2 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -22.01% per trade.
---